

Traverse secures licence to academic assets

BY JOSEPH HARVEY



US firm Traverse Biosciences has gained access to a library of polyenolic zinc-binding agents, which it will use in the animal health industry.

The New York-based business has signed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York. The deal provides Traverse with drug candidates, which can be used to treat inflammation.

The drugs are subject to four pending patent applications in the US and Europe. The license also gives Traverse the exclusive option to license the human health applications of the drug candidates.

The co-inventors of the candidates have joined the Traverse team – Dr Lorne Golub, distinguished professor at the Department of Oral Biology and Pathology within the Stony Brook University School of Dental Medicine, and Dr Francis Johnson, professor of chemistry and pharmacology also at Stony Brook University.

The doctors have taken scientific co-founder roles at Traverse. Peter Donnelly, director of the Office of Technology Licensing and Industry Relations at Stony Brook University, has been appointed to represent the Research Foundation on Traverse's board.

Traverse is currently developing its lead candidate, TRB-N0224, to treat periodontal disease in humans and animals.

RESEARCH & DEVELOPMENT